OYST has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OYST has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year. Oyster Point Pharma's 1-Year ROIIC % for the quarter that ended in Sep. 2022 was -765.21%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Oyster Point Pharma's 1-Year ROIIC % or its related term are showing as below:
The historical data trend for Oyster Point Pharma's 1-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oyster Point Pharma Annual Data | |||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | ||||||
1-Year ROIIC % | - | - | - | - | - |
Oyster Point Pharma Quarterly Data | |||||||||||||||||||
Dec17 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | |
1-Year ROIIC % | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Oyster Point Pharma's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Oyster Point Pharma's 1-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Oyster Point Pharma's 1-Year ROIIC % falls into.
Oyster Point Pharma's 1-Year ROIIC % for the quarter that ended in Sep. 2022 is calculated as:
1-Year ROIIC % | = | 1-Year Incremental Net Operating Profit After Taxes (NOPAT)** | / | 1-Year Incremental Invested Capital |
= | ( -158.453 (Sep. 2022) - -79.958 (Sep. 2021) ) | / | ( 23.062 (Sep. 2022) - 12.804 (Sep. 2021) ) | |
= | -78.495 | / | 10.258 | |
= | -765.21%*** |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Oyster Point Pharma (NAS:OYST) 1-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Thank you for viewing the detailed overview of Oyster Point Pharma's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Ozawa Clare | director | ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
Link William J Phd | director, 10 percent owner | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Versant Venture Capital Vi, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Donald J Santel | director | 4362 24TH STREET, SAN FRANCISCO CA 94114 |
George Christopher Eliades | director | C/O OYSTER POINT PHARMA, INC., 202 CARNEGIE CENTER, SUITE 109, PRINCETON NJ 08540 |
Michael G Atieh | director | MERCK MEDCO MANAGED CARE INC, 100 SUMMIT AVE, MONTVALE NJ 07645 |
John Snisarenko | officer: Chief Commercial Officer | C/O ALIMERA SCIENCES, INC., 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005 |
Invopps Gp Iv, L.l.c. | director, 10 percent owner | 126 EAST 56TH STREET, 20THFLOOR, NEW YORK NY 10022 |
Vida Ventures, Llc | 10 percent owner | 40 BROAD STREET, SUITE 201, BOSTON MA 02109 |
Kkr Healthcare Strategic Growth Fund L.p. | 10 percent owner | C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019 |
Jeffrey Nau | director, officer: President and CEO | 202 CARNEGIE CENTER, SUITE 106, PRINCETON NJ 08540 |
Daniel Lochner | officer: Chief Financial Officer | 202 CARNEGIE CENTER, SUITE 106, PRINCETON NJ 08540 |
New Enterprise Associates 14, L.p. | 10 percent owner | 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093 |
Kkr Group Partnership L.p. | 10 percent owner | C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 30 HUDSON YARDS, NEW YORK NY 10001 |
Invopps Iv Us, L.p. | director, 10 percent owner | 126 EAST 56TH STREET, 20TH FLOOR, NEW YORK NY 10022 |
From GuruFocus
By Business Wire Business Wire • 11-09-2022
By Value_Insider Value_Insider • 11-02-2022
By PRNewswire PRNewswire • 11-08-2022
By PurpleRose PurpleRose • 08-08-2022
By Value_Insider Value_Insider • 12-07-2022
By Business Wire Business Wire • 12-07-2022
By GuruFocusNews GuruFocusNews • 07-05-2022
By Value_Insider Value_Insider • 11-08-2022
By GuruFocusNews GuruFocusNews • 07-05-2022
By PurpleRose PurpleRose • 07-27-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.